DINESH

Poly Medicure

Latest CMP 1,786
Today's Change ▼ -1.47%
52-Week High / Low 2,118 | 1,191
Price Date: 14-Aug-2026
Recommendation Buy
Target Price 2,362
Expected Upside 15.0%
Forecast Horizon 2 Years
Historical CAGR 22.5%
1,000 Invested 15-Aug-2006
Today's Value 57,794
Investment Period 20 Years

Stock Snapshot

Post Results Return
+6.7%
Mild Positive Re-rating
1-Year Target Price
2,042
2-Year Target Price
2,362
52-Week High / Low
2,118 / 1,191
20-Day Return
+3.8%
Market Cap (Cr.)
18,105
Current PE
51.6
P/BV Ratio
5.9
Dividend Yield
0.2%
Industry PE
40.0

Price Performance

Basis of our Recommendation

Poly Medicure is strategically transitioning from a volume-driven infusion therapy provider to a diversified global medical device platform, focusing on high-growth segments such as cardiology and renal care. Management's emphasis on integrating recent European acquisitions and expanding into emerging markets like Brazil is expected to enhance revenue streams, despite short-term margin pressures due to acquisition-related costs and logistical challenges. Vista's financial outlook anticipates stable revenue growth aligned with historical performance, although margins may face continued pressure. The company's low leverage supports financial stability, while the fair valuation reflects its intrinsic value. Industry dynamics, including the growing demand for contract manufacturing and the shift towards Indian CDMOs, provide a favorable backdrop for Poly Medicure's expansion. Over the next 12-24 months, key opportunities include leveraging India's manufacturing cost advantage and a robust product pipeline, while watchpoints include successful integration of acquisitions and managing raw material volatility

👍 Why We Like This Stock

  • Management's focus on high-growth segments and successful integration of European acquisitions is expected to drive long-term revenue growth
  • The company's strong R&D capabilities and commitment to value-based pricing enhance its competitive position in the market
  • Low leverage and a conservatively financed balance sheet provide financial stability amid expansion efforts

Things To Watch Out For

  • Short-term margin pressures due to acquisition integration and high capital expenditures may impact profitability
  • Logistical disruptions in West Asia and raw material price volatility pose risks to operational efficiency
  • Regulatory compliance across multiple jurisdictions presents ongoing challenges for the company's expansion strategy

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Improving
Analyst View
Not Available
Dividend History
Consistent
FII Holdings
Stable

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 1,375 1,669 1,875 2,053 2,333
Profit Before Tax (Cr.) 345 447 534 501 593
PBT Margin 25.1% 26.8% 2848.0% 24.4% 25.4%
Net Profit (Cr.) 267 352 332 381 451
Earnings Per Share 26.4 34.8 32.8 37.6 44.5

Analyst Recommendations

No analyst recommendations available.

Consensus Recommendation ► None
Consensus Target
Coverage 0 Analysts
Analysts' Viewpoint

Company Overview

Show Company Profile

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.